DE69809558T2 - Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2 - Google Patents
Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2Info
- Publication number
- DE69809558T2 DE69809558T2 DE69809558T DE69809558T DE69809558T2 DE 69809558 T2 DE69809558 T2 DE 69809558T2 DE 69809558 T DE69809558 T DE 69809558T DE 69809558 T DE69809558 T DE 69809558T DE 69809558 T2 DE69809558 T2 DE 69809558T2
- Authority
- DE
- Germany
- Prior art keywords
- ucp
- obesity
- diabetes mellitus
- metabolic syndrome
- dependent diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9702457A SE9702457D0 (sv) | 1997-06-26 | 1997-06-26 | Screening |
PCT/SE1998/001232 WO1999000123A1 (en) | 1997-06-26 | 1998-06-24 | Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69809558D1 DE69809558D1 (de) | 2003-01-02 |
DE69809558T2 true DE69809558T2 (de) | 2003-04-10 |
Family
ID=20407529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69809558T Expired - Fee Related DE69809558T2 (de) | 1997-06-26 | 1998-06-24 | Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1001758B1 (de) |
JP (1) | JP2002508770A (de) |
AT (1) | ATE227986T1 (de) |
AU (1) | AU744134B2 (de) |
CA (1) | CA2295747A1 (de) |
DE (1) | DE69809558T2 (de) |
NZ (1) | NZ502112A (de) |
SE (1) | SE9702457D0 (de) |
WO (1) | WO1999000123A1 (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023568A2 (en) * | 1998-10-06 | 2000-04-27 | Albert Einstein College Of Medicine Of Yeshiva University | Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells |
AU1763201A (en) * | 1999-11-10 | 2001-06-06 | Mitokor | Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery |
US6365796B1 (en) * | 2000-02-16 | 2002-04-02 | Beth Israel Deaconess Medical Center | Transgenic UCP2 knockout mouse and use thereof |
EP1294881B1 (de) | 2000-06-22 | 2004-09-15 | Genentech, Inc. | Metabolismuskontrolle mittels zusamensetzungen des humanen 2-oxoglutarat-trägers |
ES2177404B1 (es) * | 2000-07-07 | 2004-09-16 | Consejo Superior De Investigaciones Cientificas | Procedimiento para la determinacion de la actividad de las proteinas desacoplantes (ucps) mediante la monitorizacion del consumo de nad (p) h. |
WO2003002732A1 (en) * | 2001-06-27 | 2003-01-09 | Biovitrum Ab | Citrate lyase poly peptides |
AU2003214048A1 (en) * | 2002-01-25 | 2003-09-02 | Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung | Proteins involved in the regulation of energy homeostasis and organelle metabolism |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
FR2853911B1 (fr) * | 2003-04-17 | 2005-07-08 | Merck Sante Sas | Gene induit par l'insuline, comme cible therapeutique dans le diabete |
JPWO2005028647A1 (ja) * | 2003-09-22 | 2006-11-30 | 国立大学法人京都大学 | 核酸プローブ、核酸チップ、標的核酸検出方法、薬剤スクリーニング方法、標的核酸検出装置及び遺伝子診断方法 |
CA2551037A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
US7572783B2 (en) | 2004-08-13 | 2009-08-11 | Amgen Inc. | Substituted benzofused heterocycles |
BRPI0610580B8 (pt) | 2005-05-30 | 2021-05-25 | Banyu Pharma Co Ltd | composto derivado de piperidina |
WO2007018248A1 (ja) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | ピリドン化合物 |
DE602006017712D1 (de) | 2005-08-24 | 2010-12-02 | Banyu Pharma Co Ltd | Phenylpyridonderivat |
US20090264426A1 (en) | 2005-09-07 | 2009-10-22 | Shunji Sakuraba | Bicyclic aromatic substituted pyridone derivative |
US8293900B2 (en) | 2005-09-29 | 2012-10-23 | Merck Sharp & Dohme Corp | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
CA2625416A1 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
EP1944301A4 (de) | 2005-10-27 | 2012-01-04 | Msd Kk | Neue benzoxathiinderivate |
JP4371164B2 (ja) | 2005-11-10 | 2009-11-25 | 萬有製薬株式会社 | アザ置換スピロ誘導体 |
CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
WO2008047544A1 (fr) | 2006-09-28 | 2008-04-24 | Banyu Pharmaceutical Co., Ltd. | Dérivé diarylcétimine |
JP4814774B2 (ja) | 2006-12-06 | 2011-11-16 | 花王株式会社 | 肥満調節剤の評価方法 |
CA2682727C (en) | 2007-04-02 | 2016-03-22 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CA2688161C (en) | 2007-06-04 | 2020-10-20 | Kunwar Shailubhai | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
JP5099856B2 (ja) * | 2007-11-26 | 2012-12-19 | 独立行政法人科学技術振興機構 | 代謝症候群の治療もしくは予防剤、検査方法、検査薬、及び代謝症候群の治療薬の候補化合物のスクリーニング方法 |
CA2714617A1 (en) | 2008-03-06 | 2009-09-11 | Banyu Pharmaceutical Co., Ltd. | Alkylaminopyridine derivative |
US20110015198A1 (en) | 2008-03-28 | 2011-01-20 | Banyu Pharmaceutical Co., Inc. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
EP2301936A1 (de) | 2008-06-19 | 2011-03-30 | Banyu Pharmaceutical Co., Ltd. | Spirodiamin-diarylketoximid-derivat |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Msd株式会社 | 5員−5員又は5員−6員縮環シクロアルキルアミン誘導体 |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EA025380B1 (ru) | 2011-02-25 | 2016-12-30 | Мерк Шарп Энд Домэ Корп. | Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов |
KR20150036245A (ko) | 2012-08-02 | 2015-04-07 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 트리시클릭 화합물 |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
EP2970384A1 (de) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonisten der guanylatcyclase und deren verwendungen |
US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN113121450A (zh) | 2014-08-29 | 2021-07-16 | Tes制药有限责任公司 | α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂 |
US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
BR112019007543A2 (pt) | 2016-10-14 | 2019-07-02 | Tes Pharma S R L | inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
AR117122A1 (es) | 2018-11-20 | 2021-07-14 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4623619A (en) * | 1982-03-03 | 1986-11-18 | Nordisk Insulinlaboratorium | Method for the determination of liability in human individuals to develop atherosclerosis |
FR2557137B1 (fr) * | 1983-12-21 | 1986-05-23 | Centre Nat Rech Scient | Sonde d'adnc reconnaissant l'arnm de la proteine decouplante des mitochondries du tissu adipeux brun des mammiferes, procede de preparation et application |
DE793646T1 (de) * | 1994-11-23 | 1999-12-30 | Upjohn Co | Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus |
FR2733513B1 (fr) * | 1995-04-25 | 1997-07-18 | Centre Nat Rech Scient | Lignees immortalisees de cellules issues du tissu adipeux humain, leur procede de preparation et leurs applications |
US5783408A (en) * | 1995-06-07 | 1998-07-21 | Hamilton; Bradford S. | Method for screening potential anti-obesity agents |
US6566089B1 (en) * | 1996-09-04 | 2003-05-20 | Tularik Inc. | Cell-based drug screens for regulators of gene expression |
AU2809797A (en) * | 1997-01-15 | 1998-08-07 | Centre National De La Recherche Scientifique Centre De Recherche Sur L'endocrinologie Moleculaire Et Le Developpement | Respiration uncoupling protein |
-
1997
- 1997-06-26 SE SE9702457A patent/SE9702457D0/xx unknown
-
1998
- 1998-06-24 EP EP98930032A patent/EP1001758B1/de not_active Expired - Lifetime
- 1998-06-24 CA CA002295747A patent/CA2295747A1/en not_active Abandoned
- 1998-06-24 WO PCT/SE1998/001232 patent/WO1999000123A1/en active IP Right Grant
- 1998-06-24 AU AU79513/98A patent/AU744134B2/en not_active Ceased
- 1998-06-24 DE DE69809558T patent/DE69809558T2/de not_active Expired - Fee Related
- 1998-06-24 JP JP50549299A patent/JP2002508770A/ja active Pending
- 1998-06-24 AT AT98930032T patent/ATE227986T1/de not_active IP Right Cessation
- 1998-06-24 NZ NZ502112A patent/NZ502112A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU744134B2 (en) | 2002-02-14 |
JP2002508770A (ja) | 2002-03-19 |
WO1999000123A1 (en) | 1999-01-07 |
EP1001758B1 (de) | 2002-11-20 |
NZ502112A (en) | 2002-02-01 |
CA2295747A1 (en) | 1999-01-07 |
DE69809558D1 (de) | 2003-01-02 |
AU7951398A (en) | 1999-01-19 |
ATE227986T1 (de) | 2002-12-15 |
EP1001758A1 (de) | 2000-05-24 |
SE9702457D0 (sv) | 1997-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69809558D1 (de) | Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2 | |
BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
CY1112738T1 (el) | Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη | |
BR9906796A (pt) | Método para a administração de análogos de insulina monoméricos | |
NO20053678L (no) | Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser | |
ATE204754T1 (de) | Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie | |
WO2004110375A3 (en) | Combination therapy for the treatment of diabetes | |
EA200700232A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
EA200500782A1 (ru) | Лечение геморрагического шока | |
DE69400799T2 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
BR9814280A (pt) | Arilpiperazinas que apresentam atividade noreceptor 1a de serotonina | |
MY134167A (en) | Biphenylcarboxamides useful as lipid lowering agents | |
BR0011928A (pt) | Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética | |
DE50210906D1 (de) | Arzneimittel enthaltend deuterium zur behandlung der zuckerkrankheit | |
HUP0003428A2 (hu) | Leptin antagonisták alkalmazása diabetes kezelésére | |
ATE198278T1 (de) | Verwendung von sulodexid und von arzneimitteln, die dieses enthalten, zur behandlung der diabetischen nephropathie | |
DE69717301T2 (de) | Verwendung von wachstumshormone | |
BR0314713A (pt) | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias | |
DE69520430T2 (de) | Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon | |
ATE309817T1 (de) | Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs | |
BR9812531A (pt) | Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica | |
ES2181923T3 (es) | 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina. | |
EA200401454A1 (ru) | Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний | |
DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8339 | Ceased/non-payment of the annual fee |